Brian Yueh

Brian Yueh

Auto-generated profile, based on publicly available information

Brian Yueh

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2026 in Cancer Research Communications
Verified
Journal Article
Open access
CCCharlie Chung
Charlie Chung
BYBrian Yueh
Brian Yueh
SSSanthilal Subhash
Santhilal Subhash
OEOnur Eskiocak
Onur Eskiocak
ANAaron Nizam
Aaron Nizam
SBSemir Beyaz
Semir Beyaz
High-grade endometrial cancers (HGEC) disproportionately affect women of African ancestry and often resist currently available immunotherapies. Defining the mechanisms driving this resistance is impeded by a lack of preclinical models that preserve ancestral diversity and patient-matched tumor–immune interactions without confounding alloreactivity. To address this gap, we established a biobank of 85 endometrial cancer patient-derived organoids (PDO) from a diverse cohort, enriched for HGEC PDOs from African American patients, and paired these with autologous immune cells to develop a patient-specific PDO–immune cell coculture platform with real-time live-imaging readouts. Using this system, we found that HGECs evade immune surveillance through pronounced suppression of major histocompatibility complex (MHC) class I and II antigen presentation pathways relative to their matched normal counterparts. Restoring antigen presentation, either by IFNγ stimulation or epigenetic reprogramming via enhancer of zeste homolog 2 inhibition, rescued MHC expression and sensitized HGEC PDOs to autologous T cell–mediated cytotoxicity. Extending the platform to NK cells revealed heightened killing of low–MHC-I PDOs. Consistent with clinical observations, mismatch repair (MMR)-deficient HGEC PDOs exhibited stronger immune engagement than their MMR-proficient counterparts. Finally, this platform enabled evaluation of the safety and efficacy of emerging immunotherapies, including protease-activatable bispecific T-cell engagers and EGFR-targeted chimeric antigen receptor T cells. Together, this sustainable, scalable, ancestrally diverse autologous PDO–immune cell coculture platform offers a robust resource for dissecting immune evasion mechanisms and accelerating the development of new immunotherapies to address disparities in endometrial cancer outcomes. Significance: The efficacy of immunotherapy for HGECs remains limited, partly because current preclinical models poorly capture tumor heterogeneity and patient-specific immune microenvironment. These cancers disproportionately affect women of African ancestry, yet most studies rely on European ancestry samples. We developed an autologous PDO and immune cell coculture platform from patients of diverse ancestries. This system enables patient-level analysis of tumor–immune interactions to support development and testing of novel immunotherapeutic strategies.

25 March 2026
Verified
Other
Open access
CCCharlie Chung
Charlie Chung
BYBrian Yueh
Brian Yueh
SSSanthilal Subhash
Santhilal Subhash
OEOnur Eskiocak
Onur Eskiocak
ANAaron Nizam
Aaron Nizam
SBSemir Beyaz
Semir Beyaz
IFNγ pretreatment enhances cancer–immune cell interactions. A, A schematic depicting the experimental flow of organoid–immune cell coculture. EC, endometrial cancer. B, Raw colocalization coefficient between PDOs and caspase-3/7 signal from vehicle- and IFNγ-treated group (no immune cells) at the end point (86 hours). C, Representative images of coculture using a HGEC PDO with or without IFNγ prestimulation and autologous PBMC, CD8, and CD4 T cells. Red and green fluorescence represent endometrial organoids and corresponding immune cells, respectively. Blue fluorescence represents active caspase-3 signals. Scale bar, 70 μm. D, Colocalization of PDOs and immune cells over the time of imaging. Colocalization coefficient (R1) was calculated as described previously (26) and normalized to the initial time point. The area under the curve was used for statistical significance (ordinary t test). E, The end point viability of PDOs in the coculture measured by colocalization coefficient between organoid and caspase-3 signals. Colocalization coefficient was calculated as described previously (26) and normalized to no immune cell control (vehicle). Cas3, caspase-3. Ordinary one-way ANOVA (E) was used to calculate statistical significance (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001).




25 March 2026
Verified
Other
Open access
CCCharlie Chung
Charlie Chung
BYBrian Yueh
Brian Yueh
SSSanthilal Subhash
Santhilal Subhash
OEOnur Eskiocak
Onur Eskiocak
ANAaron Nizam
Aaron Nizam
SBSemir Beyaz
Semir Beyaz
Enhanced MHC expression mediated by EZH2 inhibition in HGEC organoids augments cancer–T cell interactions. A, Representative images of coculture using a HGEC PDO with or without TAZ prestimulation and autologous PBMC, CD8, and CD4 T cells. Scale bar, 70 μm. B, Colocalization of PDOs and immune cells over the time of imaging. Colocalization coefficient (R1) was calculated as described previously (26) and normalized to the initial time point. The area under the curve was used for statistical significance (ordinary t test). C, End point viability of PDOs in autologous coculture measured by colocalization coefficient between organoid and caspase-3 signals. Colocalization coefficient was calculated as described previously (26) and normalized to no immune cell control (vehicle). Cas3, caspase-3. Ordinary one-way ANOVA (C) was used to calculate statistical significance (****, P < 0.0001).